APPLICATION
ANDA205533
TYPE
ANDA
ORIGINAL APPROVAL
2022-05-02
LATEST ACTION
2022-05-02
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
BORTEZOMIBPrescription
BORTEZOMIB 3.5MG/VIAL · INJECTABLE · INTRAVENOUS, SUBCUTANEOUS
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.